

# U.S. FDA Approved Immune-Checkpoint Inhibitors<sup>1-7</sup>

## Squamous Cell Head & Neck Cancer

1L/2L after platinum chemotherapy:

- nivolumab or pembrolizumab

## Malignant Melanoma

Adjuvant ipilimumab, nivolumab, or pembrolizumab

1L ipilimumab, nivolumab, or pembrolizumab

1L combination nivolumab + ipilimumab

## Merkel Cell Carcinoma

2L avelumab or pembrolizumab

## Cutaneous Squamous Cell Carcinoma

1L cemiplimab

## Hepatocellular Carcinoma

2L nivolumab or pembrolizumab after sorafenib

## Adv. Renal Cell Carcinoma

1L nivolumab plus ipilimumab

2L nivolumab after anti-angiogenic therapy

## MSI-H or dMMR Cancers

2L nivolumab in CRC

2L nivolumab plus ipilimumab in CRC

2L pembrolizumab in any MSI-H/dMMR cancer

## Cervical Cancer

2L pembrolizumab CPS $\geq$ 1

## Small Cell Lung Cancer

3L nivolumab

## Non-Small Cell Lung Cancer

Maintenance durvalumab after chemoradiation

1L pembrolizumab TPS $\geq$ 50%

1L *non-squamous* NSCLC

- pembrolizumab + pemetrexed & platinum-salt

- atezolizumab + bevacizumab, paclitaxel & carboplatin

1L *squamous* NSCLC

- pembrolizumab + carboplatin & (nab-)paclitaxel in

2L pembrolizumab TPS $\geq$ 1%

2L atezolizumab or nivolumab

## Triple-Negative Breast Cancer

1L atezolizumab + paclitaxel protein-bound PD-L1 $\geq$ 1%

## Gastric & GEJ Carcinoma

3L pembrolizumab CPS $\geq$ 1

## Classical Hodgkin Lymphoma

4L pembrolizumab

3L/4L nivolumab after auto-HSCT and BV

## PMBCL


3L pembrolizumab

## Locally Adv. or Met. Urothelial Cancer

1L/2L pembrolizumab,

1L/2L after platinum salt:

- atezolizumab, avelumab, durvalumab, or nivolumab



Copyright Photo: pixologic / 123RF

Updated on 09-Mar-2019 - citations on last page - ©medi-paper.com